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Abstract: The pathogenesis of autoimmune thyroid diseases (AITD) is poorly understood and the 
association between different immune features and the germline variants involved in AITD are yet 
unclear. We previously observed systemic depletion of IgG core fucosylation and antennary α1,2 
fucosylation in peripheral blood mononuclear cells in AITD, correlated with anti-thyroid peroxidase 
antibody (TPOAb) levels. Fucose depletion is known to potentiate strong antibody-mediated NK 
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cell activation and enhanced target antigen-expressing cell killing. In autoimmunity, this may 
translate to autoantibody-mediated immune cell recruitment and attack of self-antigen expressing 
normal tissues. Hence, we investigated the crosstalk between immune cell traits, secreted proteins, 
genetic variants and the glycosylation patterns of serum IgG, in a multi-omic and cross-sectional 
study of 622 individuals from the TwinsUK cohort, 172 of whom were diagnosed with AITD. We 
observed associations between two genetic variants (rs505922 and rs687621), AITD status, the 
secretion of Desmoglein-2 protein, and the profile of two IgG N-glycan traits in AITD, but further 
studies need to be performed to better understand their crosstalk in AITD. On the other side, 
enhanced afucosylated IgG was positively associated with activatory CD335- CD314+ CD158b+ NK 
cell subsets. Increased levels of the apoptosis and inflammation markers Caspase-2 and Interleukin-
1α positively associated with AITD. Two genetic variants associated with AITD, rs1521 and 
rs3094228, were also associated with altered expression of the thyrocyte-expressed ligands known 
to recognize the NK cell immunoreceptors CD314 and CD158b. Our analyses reveal a combination 
of heightened Fc-active IgG antibodies, effector cells, cytokines and apoptotic signals in AITD, and 
AITD genetic variants associated with altered expression of thyrocyte-expressed ligands to NK cell 
immunoreceptors. Together, TPOAb responses, dysregulated immune features, germline variants 
associated with immunoactivity profiles, are consistent with a positive autoreactive antibody-
dependent NK cell-mediated immune response likely drawn to the thyroid gland in AITD. 
Keywords: multi-omic; autoimmune thyroid diseases (AITD); genetic variants; apoptosis; antibody-
dependent cell-mediated cytotoxicity (ADCC); anti-thyroid peroxidase antibody (TPOAb) 
 
1. Introduction 
Autoimmune thyroid diseases (AITD) are a class of chronic, organ-specific disorders of the 
thyroid gland with a high genetic heritability (55–75%) [1–4] affecting approximately 5% of the 
population and with a gender disparity (i.e., women: 5–15%; men: 1–5%) [5–7]. Pathologically, AITD 
are characterized by autoantibodies against three main thyroid proteins (thyroid peroxidase (TPO), 
thyroglobulin (Tg), and the thyroid-stimulating hormone (TSH) receptor (TSH-R)), infiltration of the 
thyroid gland by immune cells (e.g., lymphocytes, NK cells, monocytes, and macrophages), the 
formation of germinal centers in the thyroid gland [8] and dysregulated TSH levels [9,10]. However, 
some studies have failed to observe a significant difference in peripheral blood immune cell 
composition between AITD patients and healthy individuals [11], while others report significant 
differences in particular cell types or in immune marker expression [12]. Immune cells, thyroid 
autoantibodies, and secreted proteins including cytokines may play critical roles in AITD 
development [13] and in immune responses, including in antibody-dependent cell-mediated 
cytotoxicity (ADCC) pathways [14,15]. However, the underlying autoimmune signatures associated 
with AITD remain unclear. 
ADCC is triggered via antigen/antibody/Fc receptor complex formation, bringing the effector 
cell (macrophages, NK cells) and the target cell (expressing the antigen) in close contact. The 
formation and function of antigen/antibody complexes are modulated by various factors including 
post-translational modifications of glycans decorating antibodies [16,17]. One example is lack of 
fucose on the N-linked core glycan of IgG. Afucosylated antibodies have a higher affinity (~100-fold) 
for the immunoglobulin Fc receptor FcγRIIIa (CD16a), expressed on NK cells, macrophages and γδ 
T cells, and are shown to confer enhanced ADCC potential in vitro and anti-tumor activity in vivo 
[18–21]. This could result in antibodies with more potent Fc-mediated effector functions able to more 
effectively recruit and activate immune effector cells such as NK cells to kill target antigen-expressing 
cells [22,23]. IgG core fucose, observed in approximately 95% of IgG in healthy individuals, is 
considered a “safe switch” that can attenuate potentially harmful antibody-dependent damage 
against self-antigen-expressing normal tissues [18–21,24]. However, it is possible that these processes 
may be altered in autoimmune diseases. 
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We previously studied the glycosylation profiles of total immunoglobulin G (IgG) and of 
peripheral blood mononuclear cells (PBMC) in patients with AITD [4], as well as the glycosylation of 
IgG-depleted serum proteins in Hashimoto’s thyroiditis (HT) patients [25]. In peripheral blood, we 
identified both depleted core fucosylation of IgG antibodies and decreased antennary α1,2 
fucosylation of PBMC to be associated with autoantibodies to thyroid peroxidase (TPOAb) and AITD 
status [4]. We also identified a network of genes, including FUT8 and IKZF1 that regulate 
fucosylation, to be implicated in the development of AITD [4,26]. Based on these findings, we 
speculated that IgG core fucose deficiencies together with elevated levels of autoantibodies may 
participate in autoimmune responses in AITD by enhancing effector cell activation and heightened 
immune and inflammatory signals. 
Therefore, here we investigated immune features that may signify dysregulated, and likely 
heightened immune effector cells, antibodies, and immune mediators in AITD. In this in silico study 
in the blood of 622 subjects from the TwinsUK cohort, of whom 172 have AITD features, we aimed 
to investigate: (1) the association of different components of antigen/antibody/Fc receptor complexes 
with AITD; (2) the associations between these different immune components in a cohort of samples 
from volunteers regardless of disease status, and (3) potential genetic drivers on these components 
(study design summarized in Figure 1). Specifically, we examined the association of total serum IgG 
glycosylation, immune traits, such as immune cell subpopulation frequencies (CSFs; i.e., relative 
frequencies of circulating immune cell subsets), immune cell surface protein expression levels (SPELs; 
i.e., the measurement of the cell-surface expression of critical proteins) and secreted proteins, in the 
peripheral blood of patients with AITD compared with those of healthy volunteers (sample sizes of 
each study performed are summarized in Table S1). 
 
Figure 1. Multi-omics computational analyses were used to study the components of 
antigen/antibody/effector cell complex structure in AITD. (1) We previously performed glycome-
wide association studies of AITD and TPOAb levels using 3146 individuals from three European 
cohorts, including the TwinsUK cohort. We identified 17 AITD-IgG N-glycan traits in the discovery 
TwinsUK cohort, and seven of these 17 have been then replicated in two other cohorts [4]. (2) In the 
present study, we studied the association of total IgG N-glycan traits with 23,485 immune cell traits 
in 383 individuals from the TwinsUK cohort (regardless of disease status). We showed that 6 out of 
Cells 2020, 9, 665 4 of 23 
 
the 17 AITD-IgG glycan traits were correlated with 51 immune cell traits featuring the CD335, CD134, 
and CD158b receptors. (3) None of these 51 immune cell traits appeared to be associated with AITD 
in 374 individuals (34 with AITD). (4) The heritability of AITD, TPOAb level and several -omic features 
(IgG N-glycan traits and immune cell traits) were performed in previous studies of the TwinsUK 
cohort [4,27–29]. Here we estimated the heritability of secreted proteins, but we could not determine 
shared additive genetic variance between different phenotypes studied (AITD status, TPOAb level, 
level of IgG N-glycan traits, of immune cell traits and of circulating proteins in the bloodstream). (5) 
We identified genetic variants that alter the expression of genes, proteins and cell-bound immune 
receptors (highlighted in this study) using the previous GWASs performed in the TwinsUK cohort or 
from GWAS catalog, eQTLs from GTEx project and pQTLs from INTERVAL project [27,28,30–35]. (6) 
We previously performed transcriptome-wide association studies of AITD, TPOAb level, and N-
glycan structures in the whole blood of approximately 300 individuals and we found no significant 
associations [4]. (7) We observed 3 out of 1113 circulating proteins tested in plasma of almost 300 
individuals shown to be associated with AITD status (TSH, Caspase-2, and Interleukin-1α). (8) Several 
secreted proteins were correlated with the level of plasma IgG glycan traits in 164 individuals, but 
none of them were also associated with AITD. The sample sizes of these different studies are described 
in Table S1. GlcNAc = N-acetylglucosamine. The numbers in black depict analyses performed 
previously [4,27–29] while the numbers in red depict analyses presented for the first time in the 
present study. 
2. Materials and Methods 
2.1. Study Sample  
The study was conducted using immune cell traits, glycosylation, proteomics, genotyping, and 
phenotypes in samples from research volunteers from the UK Adult Twin Registry (TwinsUK cohort, 
London, UK). The TwinsUK cohort is comprised of approximately 14,000 monozygotic and dizygotic 
same-sex adult twins from the UK, unselected for any particular disease or trait (Table S1). The cohort 
is of Northern European/UK ancestry and has been shown to be representative of singleton 
populations and the UK population in general [36,37]. Ethical approval was granted by the National 
Research Ethics Service London-Westminster, the St Thomas’ Hospital Research Ethics Committee 
(EC04/015 and 07/H0802/84). Informed consent was obtained from all study participants. 
2.2. Data Statement 
Multi-omic data were derived from samples in the TwinsUK cohort. Individual-level TwinsUK 
data, including phenotypes and genotypes, are not permitted to be shared or deposited due to the 
original consent given at the time of data collection. Access data can be applied for through the 
TwinsUK data access committee (http://twinsuk.ac.uk/resources-for-researchers/access-our-data/). 
2.3. Definition of AITD and Detection of TSH and TPOAb 
The study was performed using a clinical AITD definition and TPOAb as a threshold trait; it was 
not possible for AITD (Hashimoto’s disease and Graves’ disease) clinical diagnosis to be confirmed 
by a clinician. However, approximately 90% of individuals with Hashimoto’s disease, about 75% with 
Graves’ disease, <20% with other thyroid diseases, and <10% of normal individuals are known to 
have TPOAb-positivity [38–40]. Therefore, individuals were considered to have AITD if they either 
showed significantly higher than normal TPOAb serum titers (set at 3-fold higher than the threshold 
set by the manufacturer [18 IU/mL for the Abbott assay (ABBOTT Diagnostics Division, Wiesbaden, 
Germany) and 100 IU/mL for the Roche assay (Roche Diagnostics, Indianapolis, IN, USA)]) or had 
TSH serum levels >10 mIU/L. We considered individuals as controls if they had normal levels of TSH 
and a negative TPOAb titer, with no previous clinical diagnosis of thyroid disease and who were not 
treated with thyroid medications or steroids. Individuals with a history of thyroid cancer or thyroid 
surgery were excluded. Among the 622 individuals studied, 172 (27.65%) were identified with AITD, 
236 (37.94%) considered normal controls, and 214 (34.41%) have TPOAb or TSH serum levels outside 
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the normal range, but do not reach the 3-fold cutoff for inclusion in the AITD cohort. Evaluations of 
sera to measure TPOAb and TSH levels are described in Appendix A. 
2.4. Detection of IgG Glycosylation Profiling for Discovery  
Plasma specimens for analysis of IgG glycosylation was collected between 1997 and 2013 in 2279 
individuals from the TwinsUK cohort. IgG glycosylation profiling was performed on total plasma 
IgGs glycome (combined Fc and Fab glycans and all IgG subclasses) in Genos Glycoscience Research 
Laboratory (Zagreb, Croatia) using UPLC analysis of 2AB-labelled glycans (Waters Corporation, 
Milford, MA, USA). Protocol, data pre-processing and normalization in the TwinsUK cohort were 
previously described [4] (Appendix A).  
2.5. Detection of Immune Cell Traits  
Plasma samples for assessment of 78,000 immune traits were collected between 2010 and 2012 
in 669 female participants from the TwinsUK cohort using high-resolution deep 
immunophenotyping flow cytometry analysis (BD BioSciences, San Jose, CA, USA) as previously 
described [28]. 78,000 different cell surface marker combinations captured by 7 distinct 14-color 
immunophenotyping panels were detected and described immune cell subset frequencies (CSF) and 
immune cell-surface protein expression levels (SPELs). After quality control to remove immune cell 
traits that appeared as poor reproducibility or out of range, 23,485 immune cell traits from 497 
individuals of the TwinsUK cohort were analyzed. For this analysis, only 374 twins had immune cell 
traits data and TPOAb level detected by Roche immunoassay and 245 individuals in a case-control 
study by combining Roche and Abbott assays (204 controls and 41 AITD). Immune traits were 
quantile normalized residuals of a linear mixed effect model where age was included as fixed effects, 
and the batches were considered as random effects. 
2.6. Detection of Protein Profiling in Plasma 
With an aptamer-based multiplex protein assay (SOMAscan v2, SomaLogic Inc, Boulder, CO, 
USA) [41,42], 1129 proteins were measured (2013) on plasma samples collected between 2004 and 
2011 from 211 female twins of the TwinsUK cohort (Appendix A).  
2.7. Statistical Analyses 
All statistical analyses were run using R version 3.2.3. Linear mixed effect models were 
conducted using the R lme of package lme4 [43], and linear models were done in using R function lm 
of package stat. Custom R scripts developed for this study are available at this URL: 
https://github.com/TiphaineCMartin/multiomic_AITD.git. For determination of effective number of 
independent tests for different -omic data, association studies between -omics features and thyroid 
phenotypes and heritability analysis for proteins (Appendix A). 
2.8. Genome-Wide Association Analysis on IgG N-Glycan Traits 
To define genetic variants (i.e., single nucleotide polymorphisms (SNP), short insertions and 
deletions (indels)) associated with glycosylation profiles regardless of specific phenotypes in the 
TwinsUK cohort, we ran analyses with the GenABEL software package [44] designed for genome-
wide association study (GWAS) analysis of family-based data by incorporating pairwise kinship 
matrix calculated using genotyping data in the polygenic model to correct relatedness and hidden 
population stratification. Data were recently published with other datasets [26,45]. We selected 
genetic variants for each IgG N-glycan traits with a p-value under the GWAS threshold (p-value < 5 
× 10−8) and added the list of previously-defined genetic variants [29,45] (Appendix A).  
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2.9. Determination of Shared Genetic Variants and Genes between IgG N-Glycan Traits, Immune Cell Traits, 
Protein Abundance, and Thyroid Functions and Diseases 
To examine whether IgG N-glycan, immune cell traits, proteins, thyroid functions and diseases 
shared genetic variants or genes, we compared the genetic variants from GWASs on TwinsUK data 
(NHGRI GWAS catalog and other projects). As genetic variants detected by GWASs could be lead 
genetic variants but not necessarily causal genetic variants [46], we extended the list of genetic 
variants to other variants in linkage disequilibrium (LD) with an r2 threshold of 0.8 from 1000 G Phase 
1 European population. Using HaploReg V4.1 [47] and GTeX data [32,33], we extracted tissue-specific 
expression quantitative traits (eQTLs) associated with these genetic variants. 
2.10. Visualization 
Heatmaps were created in using R package ComplexHeatmap. Correlation plots were created 
with R package corrplot. Boxplots and scatter plot were created in using R package ggplot2. 
3. Results 
3.1. Depletion of IgG Core Fucose is Positively Associated with Increased CD158b+ CD314+ CD335− NK Cell 
Subset Counts  
IgG N-glycosylation is considered indispensable for the effector functions of IgG and 
inflammation control [48–52] and plays an essential role in the recognition and binding to Fc receptors 
of immune cells [51]. Using high-resolution deep immunophenotyping flow cytometry analysis in 
669 twins from the TwinsUK cohort and IgG N-Glycan traits in 2297 twins from the same cohort 
[4,27,28], we identified 383 samples with measurements of 23,485 immune cell and 17 AITD-IgG N-
glycan traits (IGP2, IGP7, IGP8, IGP15, IGP21, IGP33, IGP36, IGP42, IGP45, IGP46, IGP48, IGP56, 
IGP58, IGP59, IGP60, IGP62 and IGP63) and searched for any associations between them (Table S1).  
In our cohort, we identified 1357 independent immune cell traits among 23,485 potential tested 
immune cell traits, where the partial correlation between immune cell traits is highlighted in Figure S1a, 
20 independent IgG N-glycan traits among 75 potential tested IgG N-glycan traits, and 6 independent 
AITD-IgG N-glycan traits among 17 potential tested AITD-IgG N-glycan traits [53]. Association 
studies of total IgG N-glycan traits with immune cell traits showed that 6 of the 17 identified 
significant IgG N-glycan traits (IGP2, IGP42, IGP46, IGP58, IGP59, IGP60) previously associated with 
TPOAb level and AITD status in the TwinsUK cohort, were also associated with 51 immune cell traits, 
which are all NK cells (CD16+ CD56) featuring different combinations of 6 immunoreceptors (CD2, 
CD158a, CD158b, CD314, CD335, R7) (Table S2, Figure 2). Three IgG N-glycan traits without core 
fucose (IGP2, IGP42, IGP46) were negatively associated with the level of the activating subpopulation 
of CD16+ CD56+ CD158b− CD335+ NK cells and positively associated with the level of the CD16+ CD56+ 
CD335− effector NK cell subpopulation and with the activating subpopulation CD16+ CD56+ CD158b+ 
CD314+ CD335− NK cells [54–59]. In contrast, three other significant IgG N-glycan traits with core 
fucose (IGP58, IGP59, and IGP60) had the opposite effect associations with the same subpopulations 
of NK cells (Figure 2a). In agreement with our previous report, there are therefore negative 
correlations between the set of IgG N-glycan traits without core fucose (IGP2, IGP42, IGP46) and the 
set of IgG N-glycan traits describing IgG core fucose (IGP58, IGP59, and IGP60) [4] (highlighted in 
Figure 2b). Moreover, we observed strong correlations between these 51 immune cell traits (Figure 
2c). The presence of correlation patterns between the 17 AITD-IgG N-glycan traits (Figure 2b) as well 
as between the 51 immune cell traits (Figure 2c) is consistent with our observation of correlations 
between the 6 AITD-IgG N-glycan traits and the 51 immune cell traits (Figure 2a). When we extended 
our analysis to the 58 remaining IgG N-glycan traits also identified in our samples, but not associated 
with AITD, we observed no significant association between them and the 23,485 immune cell traits. 
Moreover, for 23,485 peripheral blood immune cell traits (Table S1), no significant association with 
AITD or TPOAb level could be identified (Figure S1b). 
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Figure 2. AITD-IgG N-glycan traits associated with a subpopulation of NK cells. (a) Heatmap of 
immune cell traits associated with AITD-IgG N-glycan traits. The 51 NK cell types were significantly 
associated with six out of 17 AITD-IgG N-glycan traits previously identified [4]. Below the heatmap, 
there are one representative of IgG core afucose (IGP2) and one representative of IgG core fucose 
(IGP7), that were both associated with AITD and TPOAb levels [4]. (b) Co-expressions between only 
17 IgG N-glycan traits previously associated significantly with AITD status and TPOAb level [4]. (c) 
Correlations between the profile of 51 immune cell traits that were associated significantly with at least 
one of 17 AITD-IgG N-glycan traits. The order of immune cell traits is the same as that in Figure 2a. 
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We conclude that a subpopulation of NK cells (CD16 + CD56) and specifically the activating 
subpopulation CD16+ CD56+ CD158b+ CD314+ CD335− NK cells is associated with fucose-depleted IgG 
in individuals with AITD. 
3.2. The AITD-Associated Genetic Variants, rs1521 and rs3094228, Alter Thyroid Cell Expression of 
Ligands for CD314 and CD158b Immunoreceptors 
The NK cell receptors, CD335 (NKp46), CD314 (NKG2D) and the killer cell immunoglobulin-
like receptors (KIRs) including CD158b, are normally associated with activated NK cell states, T cell 
co-stimulation, and mediating tumor cell lysis [55,57]. To determine whether genetic factors could 
contribute to AITD, related immune features, or their pathways, we inspected genetic variants 
associated with AITD, TPOAb levels, and immune cell traits from previous GWAS [27,28,30]. We 
then compared these with recent large-scale studies on tissue-specific expression quantitative traits 
(eQTLs) [35], mainly from the GTEx project [32–34] in blood and thyroid tissue.  
No genetic variants previously associated with AITD or other thyroid phenotypes appeared to 
be associated with the expression of CD335 or its known ligands in blood and thyroid cells. However, 
we observed that two genetic variants, rs1521 and rs3094228, associated with Graves’ disease and 
TPOAb-positivity, respectively, fall in the gene regulatory regions of MIC-A and MIC-B genes, two 
ligands of CD314 (NKG2D), and alter their gene expressions in thyroid cells [32–34,60–62] (Figure 3, 
Table S4, Figure S2). These two AITD-genetic variants, rs1521 and rs3094228, also alter the expression 
of the HLA-C gene, ligand of CD158b, in thyroid cells. The Graves’ disease (GD) risk allele of rs1521 
variant is primary associated with a reduced expression of HLA-C gene, ligand of CD158b, in thyroid 
cells. Furthermore, the TPOAb-positivity risk allele of rs3094228 variant is primary associated with 
an increased expression of MIC-B gene, ligand of CD314 (NKG2D), in thyroid cells. As about 75% of 
patients with Graves’ disease have TPOAb-positivity and rs3094228 that has been associated with 
TPOAb-positivity and Graves’ disease [61,63], it is possible that the association of rs1521 with Graves’ 
disease could be also driven by TPOAb-positivity and, so, associated with its phenotypes. 
Downregulation of HLA-C gene expression and upregulation of MIC-A and MIC-B gene expression 
in thyrocytes could activate NK cell functions and the cytokine production against thyrocytes when 
NK cells and thyrocytes are in contact.  
Furthermore, three genetic variants, rs2596460, rs2596457 and rs2523691, previously associated 
with higher levels of the subpopulation of NK cells featuring CD16+ CD56/CD2− CD314+ CD335− 
CD337− CD158a+ CD158b+ [28], are in the same haplotype as the rs3094228 genetic variant, but with a 
low linkage disequilibrium (LD, r2 < 0.8) (Table S5). Potentially, one of the genetic variants in this 
locus are the causal genetic variant of higher abundance of CD158b+ CD314+ CD335− NK cells. All of 
the three genetic variants could also alter the expression of the HLA-C gene, ligand of CD158b, and 
MIC-A, ligand of CD314 (NKG2D), in immune cells [32–34,64] (Figure 3, Table S4).  
Overall, two genetic variants, rs1521 and rs3094228, associated with, respectively, Graves’ 
disease and TPOAb-positivity, appear to alter thyrocyte expression of ligands of two 
immunoreceptors of NK cells, CD314 and CD158b; both of which have the capacity to enhance 
cytotoxicity of NK cells after binding with target cells. Additionally, three genetic variants in the same 
haplotype than rs3094228 could increase the abundance of the immune active CD158b+ CD314+ 
CD335− NK cell subpopulation. 
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Figure 3. Association of immune cell traits with AITD status. Annotation tracks around MIC-A, MIC-
B and HLA-C genes visualize significant GWAS hits for immune cell traits, the ligands of certain 
immunoreceptors (such as NK), and thyroid phenotypes previously identified in the TwinsUK cohort 
as well as chromatin states identified using chromHMM from whole blood from ENCODE [65] and 
thyroid cells from CEMT [66] and eQTLs from GTEx project [32,33]. The plot was produced using 
functions from R packages Gviz and coMET [67]. 
3.3. AITD is Associated with Increased Serum Caspase-2 and IL-1α 
We next evaluated whether the abundance of 1113 free soluble proteins, which are partially 
correlated between each other (Figure 4a), in peripheral blood may be associated with AITD status 
(27 AITD patients versus 130 healthy controls) and TPOAb levels (155 individuals of whom 25 have 
AITD) in the TwinsUK cohort (Table S1) using aptamer-based multiplex protein assay (SOMAscan) 
[68]. Firstly, we observed significant moderate correlations of the TSH levels measured by two 
clinical-certificated assays (Abbott and Roche) with the TSH levels measured by the SOMAscan assay 
(Figure 4b). 
This indicated that the SOMAscan assay could reproduce with good accuracy the estimation of 
TSH levels and probably also for other proteins. Levels of three proteins were positively associated 
with AITD status (Bonferroni multiple testing correction, p-value < 1.9 × 10−4): TSH (p-value = 8.67 × 
10−5; Beta = 0.67; SE = 0.16), Caspase-2 (CASP-2; p-value = 2.72 × 10−7; Beta = 1.10; SE = 0.20) and 
Interleukin-1α (IL-1α; p-value = 7.46 × 10−5; Beta = 0.41; SE = 0.09). We also observed higher mean 
levels of TSH in patients with AITD (meanSOMAscan = 1443.9, sdSOMAscan = 1238.5; meanclinical = 7.1 IU/mL, 
sdclinical = 10.47) or TPOAb-positivity (meanSOMAscan = 1389.9, sdSOMAscan = 1018.3; meanclinical = 5.7 IU/mL, 
sdclinical = 7.55) compared with controls (euthyroidism with TPOAb-negative) (meanSOMAscan = 851.1, 
sdSOMAscan = 368.6; meanclinical = 1.64 IU/mL, sdclinical = 0.79). Although Caspase-2 and IL-1α levels were 
associated with AITD status, Caspase-2 and IL-1α levels were not associated with TPOAb or TSH 
levels as continuous variables (p-value > 1.9 × 10−4). However, when participants were divided into 4 
categories according to TSH and TPOAb levels (Figure 4c), reflecting different clinical categories 
(hyperthyroidism, euthyroidism/TPOAb-negative, hypothyroidism and euthyroidism/TPOAb-
positive), Caspase-2 showed significantly higher mean and variance in two groups: hypothyroidism 
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and euthyroidism/TPOAb-positive (Figure 4d). The hypothyroidism and euthyroidism/TPOAb-
positivity in this cohort potentially indicate underlying Hashimoto’s thyroiditis (HT). This is because 
HT is the most common cause of hypothyroidism, spontaneous hypothyroidism (i.e., no previous 
history of thyroid ablation) is almost always caused by HT, and euthyroid individuals with TPOAb-
positivity almost always have HT when studied by cytology and histopathology [69–71]. On the other 
hand, the variance of IL-1α was significantly larger in groups with euthyroidism/TPOAb-positive 
and hyperthyroidism (Figure 4e), but there was no significant difference for their mean values. 
Hence, individuals from 4 categories have the same levels of IL-1α, but there are more inter-
individual variabilities in euthyroidism/TPOAb-positive and hyperthyroidism than 
euthyroidism/TPOAb-negative and hypothyroidism.  
In summary, we confirmed the association of the plasma TSH levels with AITD status, and we 
found two novel associations of plasma Caspase-2 and IL-1α with AITD status, but their secretion 
(mean and variance) seems to also depend on other factors associated with thyroid diseases such as 
the levels of TSH and TPOAb. 
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Figure 4. Association of circulating protein abundances with thyroid diseases and with AITD-IgG N-
glycan structures. (a) 1,113 circulating proteins were arranged in two dimensions based on the 
similarity of their secretion profiles in the serum by the dimensionality reduction technique UMAP 
[72] using R package umapr [73]. (b) Correlation of log10-transformed TSH measurements between 
two clinical FDA approved clinical immunoassays (Roche and Abbott) and SOMAscan assay in 217 
individuals (122 using Roche immunoassay and 95 using Abbott immunoassay). (c) Box plot of the 
level of circulating TSH measured by SOMAscan assay in the serum according to the group of thyroid 
status. (d) Box plot of the level of circulating Caspase-2 measured by SOMAscan assay in the serum 
according to the group of TSH. (e) Box plot of the level of circulating IL-1α measured by SOMAscan 
assay. An extreme outlier sample in the group 4 with an IL-1 α of 250,000 mg/mL was discarded for 
the analysis. (f) Heatmap of circulating protein abundances associated with AITD-IgG N-glycan 
structures. In Figure 2c–e, participants were assigned to 4 categories according to TSH level and 
TPOAb status: 1 = hyperthyroidism (TSH < = 0.1 mIU/L; 13 individuals), 2 = euthyroidism/TPOAb-
negative (0.4 < TSH > 4 mIU/L & TPOAb < 6 IU/mL (Abbott) or TPOAb < 34 IU/mL (Roche); 196 
healthy individuals), 3 = hypothyroidism (TSH > = 4 mIU/L; 21 individuals), and 4 = 
euthyroidism/TPOAb-positive (0.4 < TSH > 4 mIU/L & TPOAb > = 6 IU/mL (Abbott) or TPOAb > = 34 
IU/mL (Roche); 28 individuals). Wilcoxon-Mann-Whitney’s test has been performed between groups 
to estimate whether there are mean differences whereas Levene’s test has been performed between 
groups to estimate whether there are variance differences. 
3.4. Afucosylated IgG is Associated with Serum Levels of Several Circulating Proteins 
When we studied the correlation between the level of secreted TSH, Caspase-2 and IL-1α 
proteins and IgG N-glycan trait levels in 164 individuals of whom 27 have AITD, we found no 
significant associations (p-value > 8.3 × 10−4, Bonferroni test considering 3 independent proteins and 
20 independent IgG N-glycan traits) (Table S6, Figure 4f). However, several AITD-IgG N-glycan traits 
appeared to be associated with 7 other circulating proteins (AMHR2, BCMA, β2-microglobulin, 
ERBB1, Desmoglein-2, TRAILR4, and FCGR3B) (p-value < 3.67 × 10−5, Bonferroni test in considering 
only 227 independent proteins and 6 independent IgG N-glycan traits) (Table S6, Figure 4f). For 
example, three AITD-IgG N-glycan traits (IGP2, IGP42, and IGP46) were positively associated with 
circulating FCGR3B (FcγRIIIb or CD16b), an Fc receptor expressed by polymorphonuclear 
neutrophils (PMN), whereas three AITD-IgG N-glycan traits (IGP58, IGP59, and IGP60) were 
negatively associated with the antibody Fc receptor FCGR3B. Also, IGP56 and IGP48 were negatively 
associated with β2-microglobulin, involved in the presentation of intracellular antigens through the 
MHC class I complex; and IGP48 was positively associated with ERBB1, the epidermal growth factor 
receptor (EGFR), a checkpoint molecule associated with cellular proliferation and differentiation. 
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Overall, 12 AITD-IgG N-glycan traits (IGP2, IGP8, IGP42, IGP46, IGP48, IGP56, IGP57, IGP58, 
IGP59, IGP60, IGP62, and IGP63) were associated with serum levels of 7 circulating proteins (AMHR2, 
BCMA, β2-microglobulin, ERBB1, Desmoglein-2, TRAILR4, and FCGR3B) in the TwinsUK cohort. 
3.5. Free-Soluble Plasma Desmoglein-2 Protein is Associated with AITD Genetic Variants and Two AITD-
IgG N-Glycan Traits 
We evaluated several GWAS on secreted proteins (protein quantification locus traits, pQTL) 
[31], to determine whether the secretion of proteins associated with AITD or with AITD-IgG N-glycan 
traits are driven by AITD genetic variants. We found no genetic variants associated with any of 17 
AITD-IgG N-glycan structures that are also pQTL. However, four genetic variants associated with 
thyroid phenotypes published in the GWAS catalog (rs3761959, rs7528684, rs505922, and rs3184504) 
were also associated in cis and trans with nine circulating protein abundances (BGAT, CHSTB, DC-
SIGN, Desmoglein-2, DYR, FCRL3, GP1BA, MBL, and VCAM-1) (Table S7). None of these proteins 
were associated directly with AITD or TPOAb levels in our study. However, we found that 
Desmoglein-2 was associated with two AITD-IgG N-glycan traits, IGP8, and IGP63 [4] (Figure S3). 
Desmoglein-2 is highly expressed in epithelial cells including thyrocytes and cardiomyocytes and 
plays a role in the cell-cell junctions between epithelial, myocardial, and certain other cell types and 
is thought to be a regulator of apoptosis [74].  
Therefore, four genetic variants associated with thyroid phenotypes are also associated with 
nine secreted protein abundances, including the apoptosis regulator Desmoglein-2 in blood. 
Desmoglein-2 was also associated with two AITD-IgG N-glycan traits. 
4. Discussion 
The dysregulation of the immune system may affect several biological structures and processes 
in AITD, such as antigen/antibody/Fc receptor complex formation, possibly driven by genetic and 
environmental factors [75]. Little is known about the key players and the genetic variants identified 
in previous GWASs of patients with AITD. Targeting of self-antigen expressing tissues by immune 
cells may depend on the formation of antigen/antibody/Fc receptor complexes featuring substantial 
affinity or avidity properties. In the peripheral blood of individuals with AITD, we previously 
detected depletion in IgG core fucose that is known to enhance such interactions and may influence 
immune effector cell engagement of target cells by antibodies. We proposed that this signature is 
associated with TPOAb levels and with immune effector cell activation in patients with AITD [4]. 
Here, we reveal immune and genetic features pointing to activated NK cell subsets, thyroid cell-
derived ligands for immunoreceptors on NK cells, alongside secreted mediators of apoptosis and 
immune activation, all signals of heightened antibody and innate effector cell responses in AITD.  
We applied an in silico multi-omic approach on peripheral blood specimens from individuals 
from the TwinsUK cohort to investigate any association between immune features and genetic 
variants in AITD. In AITD patient samples, we observed increased levels of three circulating proteins 
(TSH, Caspase-2, and Interleukin-1α) and a decreased level of IgG core fucosylation associated with 
an activated subpopulation of NK cells defined primarily by the expression of CD335, CD134, and 
CD158b receptors. Our data confirms the previously reported association of plasma TSH level with 
AITD status and also reveals previously unknown potential biomarkers for AITD, which are highly 
associated with immunological activation functions, such as ADCC, apoptosis and pro-inflammatory 
pathways. Furthermore, several genetic variants previously associated with AITD appear to alter 
thyrocyte gene expression of several ligands of NK immunoreceptors and abundance of plasma 
circulating proteins. This suggest that the genetic background may also play potential roles in NK 
cell activation likely focused on thyroid cells in individuals with AITD.  
To our knowledge, no other cohorts have large datasets that are available to interrogate and 
feature the same diversity of -omics data with AITD phenotype or TPOAb levels. In our studies, we 
note an imbalance in the sample sizes between control individual groups and AITD groups. This is 
because the dataset comes from unselected twins and reflects the general European population [37], 
where approximately 5% of the population, but 5–15% for women, present individuals with AITD 
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[5–7]. To overcome such imbalances in our sample sizes and low samples sizes with large -omics data, 
we applied machine learning and non-parametric methods with correction for multiple testing. 
Another limitation in our present study is the absence of AITD clinical diagnosis confirmed by 
clinicians for all individuals. We consequently applied more stringent criteria to define patients with 
AITD versus control individuals, by using TSH and TPOAb levels (see Section 2.3 of our Materials 
and Methods). We also performed analysis on TPOAb levels, as this is considered the main clinical 
quantitative biomarker of AITD status [38–40]. Replication and meta-analysis studies on larger -omic 
datasets incorporating clinical features will help to confirm our present findings. 
Two secreted proteins (Caspase-2 and IL-1α), which play roles in apoptosis and the 
inflammatory response, were positively associated with AITD. TPOAb have been proposed to target 
thyroid cells by engaging effector cells via their Fc receptors [4,14,15,76,77], and the apoptosis protein 
Caspase-2 may represent a marker potentially signifying antibody-mediated destruction of thyroid 
cells [78]. In concordance, IL-1α, produced by activated immune, epithelial and endothelial cells in 
response to cell injury and apoptosis, is considered an apoptosis index of the target cell [79] and 
proportional to the degree of lymphoid infiltration in thyroid disorders [80]. IL-1α seems to reduce 
the thyroid epithelial barrier, even in the absence of any other signs of cytotoxicity [81]. In 
concordance, in our study we found higher levels of secreted IL-1α in AITD blood compared with 
levels in healthy individuals, and its variance was greater in euthyroidism/TPOAb-positive blood 
and in hyperthyroidism. This may signify dysregulation in cellular structures in the thyroid gland. 
Overall, Caspase-2 and IL-1α may reflect the degree of thyroid cell death or apoptosis and of 
lymphoid infiltration towards the thyroid gland.  
A subpopulation of NK cells expressing combinations of immunoreceptors (CD2, CD158a, 
CD158b, CD314, CD335, R7) was associated with the depletion of IgG core fucose in individuals with 
AITD. These included an activating NK receptor (CD314) and a differentiation receptor (CD335); 
whilst, fucose-depleted IgG was also positively associated with a subpopulation of NK cells with an 
inhibitory NK receptor (CD158b) [54–59,82]. The combination of potentially autoreactive antibodies 
with enhanced Fc domains and activated effector cells such as NK cells may signal increased 
inflammation and susceptibility to autoimmune disease [83]. Previous studies showed that 
afucosylated antibodies have a much higher affinity (100-fold) for FcγRIIIa (CD16a) and may thus 
have enhanced ADCC [84]. Moreover, ADCC via FcγRIIIa may require NK cells, but not monocytes 
or polymorphonuclear cells, and activity levels of the antigen/antibody/effector cell complexes have 
been correlated only with the NK cell numbers present in the PBMC [20]. Our associations between 
the levels of IgG core fucose and of a subpopulation of NK cells reinforce the notion that there is a 
complementarity between IgG core fucose levels and NK cells, that could influence effector cell 
potency, potentially against a range of antigens including self-antigens. 
It has been previously estimated that AITD are highly heritable (55–75%) and that most of IgG 
N-glycan traits and the immune cell traits associated with AITD are moderately heritable (Table S8) 
[4,27]. By estimating the proportion of genetic and environmental variance of 1129 proteins in our 
study using the Structural Equation Modeling and twin structures present in the TwinsUK cohort 
(Table S9), we found a small proportion of proteins having additive genetic variances in their 
heritability, in concordance with previous findings on a smaller dataset [85]. As the best model of 
heritability in AITD is only with dominant genetic variance, the shared genetic variance between 
AITD and proteins as well as with IgG N-glycan traits and immune cell traits could not be estimated 
with accuracy. However, in our study, we identified several genetic variants previously associated 
with thyroid phenotypes to be also associated with the secretion of proteins and gene expression of 
ligands of two NK cell immunoreceptors. Specifically, genetic variants, rs1521 and rs3094228, 
associated with Graves’ disease and TPOAb-positivity, alter the expression of thyroid cell-expressed 
ligands, MIC-A, MIC-B, and HLA-C, known to recognize CD314 and CD158b immunoreceptors 
expressed on NK cells. Moreover, rs3094228 falls in the same European haplotype as three genetic 
variants associated with higher abundance of the activated CD158b+ CD314+ CD335− NK cell subset. 
Thus, individuals having the AITD-risk allele of rs1521 variant have reduced expression of HLA-C 
gene and, at a lesser extent, expression of MIC-A in thyrocytes, whereas the carriers of AITD-risk 
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allele of rs3094228 genetic variant associated with TPOAb-positivity showed increased expression of 
MIC-B gene in thyrocytes and potentially higher abundance of the highly active CD158b+ CD314+ 
CD335− NK cells. Consequently, if the thyrocytes in carriers of AITD-risk alleles for CD158b and 
CD314 ligands crosstalk with the subpopulation of NK cells with CD158b and CD314 
immunoreceptors with the help of the antibodies, they could trigger the production of cytokines and 
cytotoxicity against thyrocytes by these NK cells.  
5. Conclusions 
Our findings thus highlight different immune features (glycan structures on antibodies, a 
subpopulation of immunoactive NK cells, the secretion of Caspase-2 and IL-1α) as potential signals 
of AITD status detectable in the bloodstream in addition to TSH and TPOAb levels. Moreover, if one 
speculates that active antibodies with low core-fucose might be thyroid autoantibodies (e.g., TPOAb) 
[86] and target cells are thyroid cells, it is conceivable (Figure 5) that that immune cell-antibody-target 
cell interactions may lead to cytotoxicity functions targeting thyroid tissues [76,86,87]. Together, these 
may form part of a dysregulated autoimmune response in AITD. Further replication studies and 
validation studies of real-time functional evaluations associated with these immune features and 
genetic analyses are needed to confirm this model. These features could also be tested in the context 
of thyroid cancer immunotherapy [77] in future studies. 
 
Figure 5. Model of different potential contributing players and their pathways activated in proposed 
antibody-dependent NK cell-mediated cytotoxicity in the thyroid gland of AITD patients. (1) The 
depletion of IgG core fucose was associated with TPOAb level and AITD status [4]. (2) The IgG N-
glycan traits associated with AITD were also associated with a subpopulation of NK cells in our 
current study; for example, the depletion of IgG core fucose is associated positively with NK cells 
with the patterns of co-receptors CD335− or CD335− CD158b+ CD314+. (3) Previous studies showed 
that afucosylated antibodies had increased affinity for binding to CD16 (FcγRIIIa), cell receptors of 
NK cells, and to enhance ADCC [18–21] via (4) protein tyrosine kinase-dependent pathways, through 
crosstalk with (5) NKG2D receptor (CD314) [88,89]. (6) Two SNPs, rs3094228 and rs1521, were 
associated with GD and TPOAb-positivity [60–62] and fall in gene regulatory regions of the MIC-A 
and MIC-B genes and increase their expression in thyroid cells [32]. These two genes encode heavily 
glycosylated proteins that are ligands for the NKG2D type II receptor (CD314). (7) The KIR2DL 
(CD158b) receptor is known to regulate the cytotoxicity of NK cells by unknown pathways, whereas 
(8) the NCR1 (CD335) receptor can contribute to the increased potency of activated NK cells to 
mediate cell lysis by unknown pathway [54,55]. (9) The SNP, rs1521 associated with GD [60], is also 
shown to reduce the expression of HLA-C gene, producing the ligand of CD158b, in thyroid cells 
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[32,33,58,59]. (10) All together (the binding of NK cells with target cells through antibodies and their 
ligands), these lead to the activation of NK cells, which release cytotoxic granules containing perforin 
and granzymes. This release mediates ADCC of target cells (3), which are thyrocytes in AITD. Also, 
(11) a positive association between the circulation abundance of Caspase-2 protein and AITD were 
found in this study that could be associated with the destruction of thyrocytes. (12) A positive 
correlation of circulating abundance of IL-1α with AITD was also found in the bloodstream that could 
be a marker of lymphocyte infiltration in the thyroid gland of individuals with AITD, and thus of 
inflammation [80,81]. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Immune cell 
traits and AITD status. (a) Immune cell traits were arranged in two dimensions based on the similarity of their 
quantification profiles by the dimensionality reduction technique UMAP [72] using R package umapr [73]. Some 
clusters that emerge spontaneously can be associated with specific immune cell types (colors). (b) Overview of 
associations observed between IgG core-fucose, a subpopulation of NK cells and AITD status in the TwinsUK 
cohort. * = glycome-wide association studies of AITD and TPOAb levels that were previously performed [4]. 
Figure S2: Overview of associations between AITD-SNP and eQTL in thyroid and blood cells. * = genome-wide 
association studies of AITD and TPOAb-positivity that were previously performed, and the findings are 
available via GWAS catalog [30] whereas ** = eQTLs that come from GTEx project [34] and Westra and al. [35]. 
(a) Associations between AITD-SNP and eQTL in thyroid and blood cells for the genetic variant rs3094228. (b) 
Associations between AITD-SNP and eQTL in thyroid and blood cells for the genetic variant rs1521. Figure S3: 
Overview of multi-omic findings associated with Desmoglein-2 in individuals with AITD status and general 
population. We highlighted a locus with high LD having SNPs and two IgG glycan traits that are both associated 
with GD and the abundance of secreted plasma Desmoglein-2 in plasma. However, no direct association of AITD 
status with the abundance of secreted plasma Desmoglein-2. We previously performed glycome-wide 
association studies of AITD and TPOAb levels [4]. Genome-wide association studies of AITD and TPOAb-
positivity were previously performed, and the findings are available via GWAS catalog [30] whereas pQTLs 
come from INTERVAL project [31]. IGP8 = the percentage of FA2[3]G1 glycan in total IgG glycans. IGP63 = The 
percentage of fucosylation (without bisecting GlcNAc) of agalactosylated structures. Table S1: Description of 
TwinsUK cohort used for different analysis performed here, Table S2: Significant glycome associations with 
immune cell traits in the TwinsUK cohort, Table S3: Associations of 51 immune cell traits with AITD and TPOAb 
level in the TwinsUK cohort, Table S4: Hits from selected eQTL studies for two SNPs, rs1521 and rs3094228 in 
the thyroid cells and whole blood, Table S5: Genes reported for genetic variants associated with thyroid 
phenotypes and immune cell traits, Table S6: Glycome-wide associations studies of 17 AITD-IgG N-glycan traits 
with 1113 circulating proteins. Only significant ones were put here, Table S7: Genetic variants associated with 
thyroid phenotypes and AITD-IgG N-glycan traits overlapping pQTL identified in INTERVAL project (LD r2 > 
0.8), Table S8: Heritability of AITD, 17 IgG N-glycan traits and 51 immune cell traits in the TwinsUK cohort, 
Table S9: Heritability of 1,113 proteins in the TwinsUK cohort. 
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Appendix A 
Appendix A.1. Detection of TSH and TPOAb in Human Sera 
Sera to assess TPOAb and TSH levels were collected by a trained nurse or phlebotomist using 
venipuncture and a SafetyLokTM Blood Collection Kit (21G3/4 Needles) and plain 10 mL serum-
separating tube vacutainer (no additives) between February 1994 and May 2007. After collection from 
the study subject, whole blood was held at 22 °C for 50 min at room temperature for a clot to form 
and serum separated within 60 min of collection. Processing of blood was performed using a 
refrigerated (4 °C) clinical centrifuge at 3000× g for 10 min with the serum supernatant subsequently 
collected, transferred to a 2 mL screw capped Nunc Cryotubes and immediately frozen at −80 °C and 
kept frozen in 2 mL screw capped Nunc Cryotube at −80 °C until use. Quantitative determination of 
TSH and TPOAb (only IgG class) levels was performed on the sera either by a chemiluminescent 
microparticle immunoassay (CMIA) [ARCHITECT® Anti-TPO or TSH (ABBOTT Diagnostics 
Division, Wiesbaden, Germany, 2005)] (TPOAb titer > 6 mIU/L considered positive; reference range 
for TSH level 0.4–4.0 mIU/L) or by an electrochemiluminescence immunoassay “ECLIA” [Elecsys and 
Cobas e analyzers, (Roche Diagnostics, Indianapolis, IN, USA, 2010)] (TPOAb titer > 34 IU/mL 
considered positive; reference range for TSH 0.4–4.0 mIU/L).  
Appendix A.2. Detection of IgG Glycosylation Profiling 
For IgG glycosylation analysis, using UPLC analysis of 2AB-labelled glycans, chromatograms 
(Waters Corporation, Milford, MA, USA) were separated in the same manner into 24 peaks, and the 
amount of glycans in each peak was expressed as a percentage of the total integrated area. One glycan 
was excluded before any transformation and standardization of data because of its co-elution with a 
contaminant that significantly affected its values in some samples whereas two glycan peaks (GP) 
GP20 and GP21 (Zagreb code) were combined into a single trait called GP2021 (Zagreb code) because 
of difficulty in distinguishing between these peaks in some samples. A global normalization and 
natural logarithm transformation were applied to 22 directly measured glycan structures. As many 
of these structures share the same structural features (galactose, sialic acid, core-fucose, bisecting N-
acetylglucosamine (GlcNAc)), 55 additional derived traits were calculated that average these features 
across multiple glycans from the 22 normalized and non-transformed directly measured glycans. 
Technical confounders (batch and run-day effects) were addressed using R package ComBat. The 22 
directly measured glycans and 55 derived glycan traits were centered and scaled to have a mean of 0 
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and standard deviation (SD) of 1. Samples being more than 6 SD from the mean were considered as 
outliers and excluded from the analysis. 
Appendix A.3. Detection of Protein Profiling in Plasma 
Plasma protein profiling was conducted using SOMAscan v2 (SomaLogic Inc, Boulder, CO, 
USA) as previously described [29,30]. Briefly, hemolyzed samples were first excluded. Proteins were 
then measured using a SOMAmer-based capture array called “SOMAscan.” Quality control was 
performed at the sample and SOMAmer level and involves the use of control SOMAmers on the 
microarray and calibration samples. At the sample level, hybridization controls on the microarray 
are used to monitor sample-by-sample variability in hybridization, while the median signal over all 
SOMAmers is used to monitor overall technical variability. The resulting hybridization scale factor 
and median scale factor are used to normalize data across samples. The acceptance criteria for these 
values are 0.4–2.5, based on historical trends in these values. Somamer-by-somamer calibration 
occurs through the repeated measurement of calibration samples; these samples are of the same 
matrix as the study samples and are used to monitor repeatability and batch to batch variability. 
Historical values for these calibrator samples for each SOMAmer are used to generate a calibration 
scale factor. The acceptance criteria for calibrator scale factors is that 95% of SOMAmers must have a 
calibration scale factor within ±0.4 of the median. For the current analysis, only 1113 proteins were 
then studied.  
Appendix A.4. Selection of SNPs Associated with Immune Cell Traits 
To define the list of SNPs associated with immune cell traits regardless to any specific 
phenotypes in the TwinsUK cohort, we extracted SNPs for each immune cell traits that have a p-value 
under GWAS p-value threshold (p-value < 5 × 10−8) from previous published GWASs on these immune 
cell traits [27,28]. To define the list of SNPs associated with protein abundance found in this study, 
we extracted the significant SNPs reported in INTERVAL project [31]. To define the list of SNPs 
associated with gene expression (eQTL), we extracted the eQTLs reported significant by GTEx and 
previous papers present in HaploReg V4.1 [47]. To define the list of SNPs associated with AITD and 
thyroid functions, we selected to SNPs listed in the NHGRI GWAS catalog [52] with words “thyroid” 
or “Graves” or “Hashimoto.” 
Appendix A.5. Determination of Effective Number of Independent Tests for Different -omic Data 
Due to high and partial correlations within glycans, proteins and immune cell traits, we decided 
to use the Equation (5) proposed by Li and Ji [45] to define an effective number (Meff) of independent 
tests. We then used this number to define the effective Bonferroni p-value threshold such as 0.05/Meff 
instead of 0.05/M, with M the actual number of tests. 20 independent tests were estimated for 76 
glycans. Consequently, to account for multiple testing in the discovery cohort, we present results 
surpassing a conservative Bonferroni correction assuming 20 independent tests, thus giving a 
significant threshold of (p-value < 2.5 × 10−3 = 0.05/20). 1357 independent tests were estimated for 
23,485 immune cell traits, thus giving a significant threshold of 3.68 × 10−5 (0.05/1,357). 227 
independent tests were estimated among 1113 proteins (p < 0.05/227 = 1.9 × 10−4). 
Appendix A.6. Association Studies between -omics Features and Thyroid Phenotypes 
To examine whether one of the 17 AITD-IgG N-glycan traits was significantly associated with 
one of the 23,485 immune cell traits, we compared the fitted model in Equation (A2) with a model 
that did not include the residual of glycan in Equation (A1): 
Model null: Yi~a + h (fixe intercepts) + g (random intercepts) + εij (A1) 
Model 1: Yi~a + bGij + h (fixe intercepts) + g (random intercepts) + εij (A2) 
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where Yi represents the quantification of immune cell traits for individual i and Gij is glycan structure 
of type j among 75 N-glycans for the same individual i. If biological covariates (age, sex) have not 
been adjusted before association analysis, they have been added in the model. A random intercept 
was added only in the discovery cohort in order to model the family-relatedness. 
To examine whether an immune cell trait was significantly associated with TPOAb level and 
AITD status, we compared the fitted model in Equation (A2) with a model that did not include the 
immune cell traits in Equation (A1) where Gij become the immune cell trait of type j among 23,485 in 
discovery cohort for the same individual i. For the discovery and replication cohorts in TwinsUK, we 
added a random intercept in order to model the family-relatedness.  
To examine whether one of the 1113 protein was significantly associated with TPOAb level and 
AITD status, we compared the fitted model in Equation (A2) with a model that did not include the 
protein in Equation (A1): where Gij become the protein of type j among 1129 in discovery cohort for 
the same individual i. We added a random intercept in order to model the family-relatedness. To 
examine whether one of 1113 proteins was significantly associated with one of 17 significant glycans, 
we compared the fitted model in Equation (A2) with a model that did not include the protein in 
Equation (A1): where Gij become the protein of type j among 1129 in discovery cohort for the same 
individual i. We added a random intercept in order to model the family-relatedness.  
Appendix A.7. Heritability Analysis for Proteins 
Using twin data and ADCE models (additive genetics (A), dominant genetics (D), shared 
environment (C) and non-shared environment (E)), heritability of glycosylation structures, immune 
cell traits and AITD were estimated using the R package called mets that allows us to run the analysis 
with monozygotic and dizygotic twins as well as unrelated individuals. The significance of variance 
components A, D, and C was assessed by dropping each component sequentially from the full model 
(ADCE) and comparing the sub-model fit to the full model. Sub-models were compared to full 
models by hierarchical χ2 tests. The difference between log-likelihood values between sub-model and 
full model is asymptotically distributed as χ2 with degrees of freedom (df) equal to the difference in 
df of sub-model and the full model. A statistical indicator of goodness-of-fit is the Akaike information 
criterion (AIC), computed as χ2 − 2df; sub-models are accepted as the best-fitting model if there is no 
significant loss of fit when a latent variable (A, C, D, or E) is fixed to equal zero. When two sub-
models have the same AIC compared to the full model, we decide to keep the model the most likely 
(with additive genetic variance) or with the lowest p-value for different components. 
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